NCT06848387 Unbound Cloxacillin Concentrations During Continuous Infusion
| NCT ID | NCT06848387 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Emeli Månsson |
| Condition | Staphylococcal Infections |
| Study Type | INTERVENTIONAL |
| Enrollment | 25 participants |
| Start Date | 2026-01-14 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 25 participants in total. It began in 2026-01-14 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cloxacillin is the first-line choice for the treatment of severe infections caused by the bacterium Staphylococcus aureus in Sweden. Over the past year, cloxacillin is increasingly administred through continuous infusion. In this study, the free (unbound) concentration of cloxacillin when administered as a continuous infusion will be measured to ensure that the free concentration is neither too high nor too low. A PK/PD model will be developed to predict which dosage of cloxacillin is appropriate for an individual based on age, gender, kidney function, and serum-protein level.
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older * Treating physician has decided to start continuous infusion of cloxacillin Exclusion Criteria: * Unwilling or unable to provide written informed consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06848387 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Staphylococcal Infections. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06848387 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06848387 currently recruiting?
Yes, NCT06848387 is actively recruiting participants. Contact the research team at emeli.mansson@regionvastmanland.se for enrollment information.
Where is the NCT06848387 trial being conducted?
This trial is being conducted at Västerås, Sweden.
Who is sponsoring the NCT06848387 clinical trial?
NCT06848387 is sponsored by Emeli Månsson. The trial plans to enroll 25 participants.